eXoZymes Inc Stock Price, News & Analysis

eXoZymes (NASDAQ:EXOZ), a company developing AI-engineered enzymes for sustainable feedstock transformation, announced its Q1 2025 financial results and operational updates. The company reached a significant milestone with the launch of its subsidiary NCTx, focused on commercializing the eXoZymes platform with N-trans-caffeoyltyramine (NCT).

Financial highlights include operating expenses of $1.95 million, primarily attributed to expanded R&D and leadership hiring. The company maintains $8.51 million in cash and cash equivalents, sufficient to fund operations into 2026. As a pre-revenue company, eXoZymes continues to focus on efficient execution and capital allocation while progressing toward value inflection points.

eXoZymes (NASDAQ:EXOZ), a company specializing in AI-engineered enzymes for sustainable feedstock transformation into nutraceuticals, medicines, and essential chemicals, has announced a webinar scheduled for Monday, May 12, 2025, at 5:00 PM Eastern Time. The event will cover the company's first quarter 2025 results and provide updates on their newly formed subsidiary, NCTx.

CEO Michael Heltzen will lead the presentation alongside management team members, discussing recent developments, ongoing initiatives, and upcoming milestones. The webinar will include a Q&A session and can be accessed through pre-registration or the company's investor relations website.

eXoZymes (NASDAQ:EXOZ) has launched a new subsidiary, NCTx, focused on developing N-trans-caffeoyltyramine (NCT), a rare plant compound with potential applications in liver and gut health. Using eXoZymes' AI-driven platform, NCTx has developed a proprietary approach to biomanufacture NCT, overcoming previous sourcing limitations where it was only found in trace amounts (less than 0.014%) in hemp seeds.

The company completed proof of concept in just 6 weeks and established the subsidiary in 12 weeks, demonstrating unprecedented speed in bio-manufacturing innovation. Pre-clinical studies show NCT's potential in treating Non-Alcoholic Fatty Liver Disease (NAFLD), which affects over 30% of the global population. The target market for bioactive ingredients in functional food is valued at $216 billion with a 7.6% CAGR globally.

eXoZymes Inc. (NASDAQ: EXOZ) is featured as the cover story in the April 2025 issue of GEN Biotechnology, introducing the scientific definition of 'exozymes' to clarify the cell-free biomanufacturing field. The peer-reviewed Open Access paper titled 'Exozymes for Biomanufacturing: Toward Clarity and Precision in the Cell-Free Space' aims to distinguish cell-free biomanufacturing from other cell-free technologies.

The paper, co-authored by experts from institutions including NREL, UCLA, Caltech, and University of Colorado Boulder, defines exozymes as industrial biomanufacturing methods that produce chemicals without using living cells. The terms 'exozymes' and 'exozyme systems' are introduced to facilitate better understanding among investors, scientists, and the public, with no trademarks filed to ensure free usage by the scientific community.

eXoZymes (NASDAQ: EXOZ) has launched BioClick, a groundbreaking enzyme engineering initiative supported by a $300K NIH grant. The project focuses on enhancing group transfer reactions in enzyme engineering, particularly prenylation, to improve drug development and biomanufacturing processes.

BioClick introduces what the company calls the 'third generation of enzyme engineering: Artificial Evolution', following directed evolution and rational protein design. The platform incorporates AI and high-throughput screening capabilities, enabling simultaneous testing of thousands of enzyme variations using mass spectrometry and advanced data analysis algorithms.

The technology aims to accelerate the development of new drugs and improve existing ones by enabling the creation of previously inaccessible small molecules. The project specifically targets the enhancement of drug compounds' functionality and effectiveness through precise molecular modifications.

eXoZymes (NASDAQ: EXOZ) has appointed Damien Perriman as Chief Commercial Officer (CCO) in a newly created role. Perriman brings over 20 years of experience in commercializing biotechnologies across nutrition, personal care, plastics, textiles, fragrances, performance fuels, and specialty chemicals markets.

Previously holding commercial leadership positions at Genomatica (Geno) and Gevo, Perriman also serves as Chairman of Danish biotech startup Cellugy. The appointment aligns with eXoZymes' strategic focus on scaling and commercializing biosolutions for sustainable feedstock transformation into essential chemicals, medicines, and biofuels.

The company will discuss this appointment during their Q4 and full-year 2024 results conference call scheduled for 4:30 PM Eastern / 1:30 PM Pacific.

eXoZymes (NASDAQ: EXOZ), a pioneer in AI-engineered enzymes for sustainable feedstock transformation, has provided its Q4 and full-year 2024 update. The company successfully completed its IPO on November 13, 2024, despite challenging market conditions for biotech fundraising.

As a pre-revenue company, eXoZymes has developed a proprietary AI-based process for generating signal-rich enzyme data to train ML algorithms, significantly accelerating their enzyme development process. The company is focusing on commercialization through spin-outs, joint-ventures, and licensing deals to expedite market entry across multiple sectors.

Their technology aims to transform sustainable feedstock into:

• Essential nutraceuticals
• Medicines
• Biofuels
• Other valuable chemicals

eXoZymes (NASDAQ: EXOZ), a company specializing in AI-engineered enzymes for converting sustainable feedstock into chemicals, medicines, and biofuels, has announced its upcoming fourth quarter and full year 2024 financial results conference call. The webinar is scheduled for Wednesday, April 2, 2025, at 4:30 p.m. Eastern Time.

CEO Michael Heltzen will lead the presentation alongside management team members to discuss quarterly results, recent developments, ongoing initiatives, and future milestones. A press release containing detailed financial results will be published before the call. Investors can access the webinar through pre-registration or the company's investor relations website.

eXoZymes (NASDAQ: EXOZ) announced significant leadership changes in its board of directors. Mo Hayat has stepped down as Chairman and President to focus on new ventures at MDB Capital. Edgardo Rayo, who initially discovered the scientific co-founders at UCLA, joins the board representing MDB Capital. Christopher Marlett, current board member and CEO of MDB Capital, will become Chairman.

Michael Heltzen, CEO of eXoZymes, will now also serve as President. The transition follows the company's recent rebranding from Invizyne Technologies and ticker change to 'EXOZ' on February 12, 2025. eXoZymes specializes in AI-engineered enzymes that transform sustainable feedstock into essential chemicals, medicines, and biofuels.